تفاصيل مارك
| 000 -LEADER |
|---|
| fixed length control field |
06983namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GICUC |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20260503114615.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
260503s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
615.1 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.08.08.Ph.D.2025.Al.M |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Alaa Subhi Mahmoud Eita, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Management of bacterial infections by advanced drug delivery systems / |
| Statement of responsibility, etc. |
by Alaa Subhi Mahmoud Eita ; Supervision Prof. Dr. Amna Mohamad AwadAllah Makky, Prof. Dr. Islam Ahmed Hamed Khalil. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
علاج العدوى البكتيرية من خلال استخدام أنظمة توصيل دوائية متطورة |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
146 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D) -Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 126-146. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Amlodipine, a well-known antihypertensive agent, has shown promising antibacterial potential, particularly against resistant bacterial strains. Utilizing nanoparticle-based delivery systems enhances the therapeutic performance by improving drug stability, bioavailability, and controlled release. The development of an optimized formulation is critical to achieving maximum antibacterial efficacy and efficient delivery. The nanotechnological approach highlights the potential of drug repurposing combined with formulation optimization as an effective strategy to overcome antimicrobial resistance and improve therapeutic outcomes. <br/>The thesis is organized into two chapters: <br/>Chapter 1: Repurposing amlodipine as an antibacterial topical formulation for skin infection.<br/>This study investigates the antibacterial potential of amlodipine (AML) by formulating it into Pluroleosomes (PLOs), lipid-based vesicles composed of soya lecithin, oleic acid, and Pluronic F-127, designed to enhance drug solubility, skin penetration, and topical delivery efficiency. A D-optimal mixture design was employed to optimize formulation variables and identify the most effective composition that achieves favorable particle size, polydispersity index, zeta potential, and entrapment efficiency. The optimized AML-PLO formulation was incorporated into a foam system to facilitate uniform application and improve dermal permeation. Characterization studies confirmed the nanoscale, spherical morphology and chemical compatibility of the formulation components. The AML-PLOs foam formulation exhibited sustained drug release and effective penetration through skin layers. Both in-vitro antibacterial assays and in-vivo wound healing studies demonstrated significant antibacterial efficacy against MRSA, supporting the potential of the optimized AML-PLO foam as a novel and effective nanocarrier system for the topical treatment of bacterial infections and as a promising example of drug repurposing through formulation optimization. <br/>Chapter 2: Repurposing amlodipine as an antibacterial topical formulation for ocular infection.<br/>This study investigates the antibacterial potential of amlodipine (AML) through its incorporation into polymeric zein nanoparticles (AML-ZNs) designed to enhance ocular drug delivery and overcome physiological barriers. A Box–Behnken design was employed using Design-Expert® software to optimize formulation parameters, including zein, Labrafac, and Poloxamer 407 concentrations, to achieve minimum particle size and polydispersity with maximum zeta potential and entrapment efficiency. The optimized AML-ZNs formulation was subsequently coated with sodium alginate to improve system stability, control drug release, and adjust viscosity for practical use as eyedrops. Characterization confirmed the presence of uniform nanospherical particles with favorable physicochemical properties and sustained release behavior. The alginate-coated formulation exhibited controlled drug release, enhanced ocular penetration, and maintained stability and sterility. In-vitro antibacterial assays and in-vivo ocular studies demonstrated the potent antibacterial activity of amlodipine against MRSA, supporting its potential repurposing as an effective antimicrobial agent. Overall, the optimized AML-ZNs–Alg system presents a promising nanocarrier platform for safe and efficient ocular drug delivery in the treatment of bacterial infections |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
<br/>يُعد الانتشار المرتفع للسلالات البكتيرية المقاومة من أبرز التحديات في علاج العدوى البكتيرية. وقد أدى تصاعد مقاومة الميكروبات للمضادات الحيوية التقليدية إلى ضرورة إجراء أبحاث مستمرة تهدف إلى اكتشاف استراتيجيات مبتكرة أو كيانات كيميائية جديدة قادرة على التغلب على هذه السلالات المقاومة.<br/>يُعتبر اكتشاف كيان كيميائي جديد ذي فعالية مضادة للبكتيريا أمرًا معقدًا، ويتطلب جهدًا كبيرًا واستثمارًا ماليًا ضخمًا. لذلك، أصبح الاعتماد على إعادة توظيف الأدوية خيارًا متزايدًا للسيطرة على مقاومة البكتيريا، من خلال تحديد أدوية بديلة ذات خصائص مضادة للبكتيريا مكتشفة حديثًا. وقد أظهرت عدة فئات علاجية فعالية ضد السلالات المقاومة، بما في ذلك المكورات العنقودية الذهبية المقاومة للميثيسيلين (MRSA)، مثل مضادات الالتهاب غير الستيرويدية، وأدوية الروماتيزم، ومضادات الاكتئاب، ومضادات الطفيليات، وأدوية السكري. ويُفضل استخدام أنظمة النواقل النانوية بالتوازي مع استراتيجية إعادة التوظيف لتعزيز النفاذية، وتنظيم إطلاق الدواء، وضمان أقصى فعالية علاجية. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmaceutics |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
الصيدلانيات |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
amlodipine |
| -- |
repurposing |
| -- |
pluroleosomes |
| -- |
zein |
| -- |
foam |
| -- |
eye drops |
| -- |
bacterial infection |
| -- |
MRSA |
| -- |
أملوديبين |
| -- |
إعادة توظيف |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Amna Mohamad AwadAllah Makky |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Islam Ahmed Hamed Khalil |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2025 |
| Supervisory body |
Amna Mohamad AwadAllah Makky |
| -- |
Islam Ahmed Hamed Khalil |
| Universities |
Cairo University |
| Faculties |
Faculty of Pharmacy |
| Department |
Department of Pharmaceutics and Industrial Pharmacy |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |